


INTEREST 2020



INTERNATIONAL CONFERENCE ON HIV TREATMENT, PATHOGENESIS,
AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS

VIRTUAL CONFERENCE | 30 NOVEMBER-4 DECEMBER 2020



PROGRAMME BOOK



AMSTERDAM INSTITUTE FOR
GLOBAL HEALTH & DEVELOPMENT



www.interestconference.org

Table of Contents

Welcome	3
Objectives	4
Practical Information	5
Time Zones	6
Committees	8
Programme	13
Acknowledgement	24



Welcome

Dear Colleagues,

Welcome to the 14th INTEREST Conference November 30-December 4, 2020 and the conference pre-week November 23-27!

Since 2014, we have dedicated the annual INTEREST Conference to the memory of Professor Joep Lange and Jacqueline van Tongeren of the Amsterdam Institute for Global Health and Development. Pivotal in establishing the INTEREST conference as a leading African and international forum for the dissemination of HIV science and practice, they died tragically when Malaysian Airlines flight MH17 was shot down over Ukraine on July 17, 2014.

The INTEREST Conference is now a recognised fixture in the HIV conference calendar. It focuses on HIV treatment, pathogenesis, and prevention in resource-limited settings, particularly in Africa. Young researchers and established international HIV experts share original research and state-of-the-art reviews on a wide range of HIV and related topics. In light of the SARS-CoV-2 pandemic, the 14th INTEREST conference was initially postponed from the face-to-face conference that had been planned for Windhoek, Namibia in May to the first week of December. A decision was made in late August 2020 to move to a virtual format, which has proven to be a wise move, given that the pandemic is continuing to expand as INTEREST pre-week activities are about to start.

The 14th INTEREST conference offers lectures, abstract-driven oral and poster sessions, and symposia but this year there will be no debates or meet-the-expert lunches. The main conference programme runs from 13:30-16:30 South Africa standard time November 30 -December 4. The pre-week November 23rd to 27th includes pre-meetings, a scientific writing skills building workshop, and poster gallery viewing. Parallel sessions on Wednesday the 25th, Thursday the 26th, and Friday 27th offer 3 activities: 1) guided poster tours, 2) Joep Lange mentoring sessions, and 3) grantspersonship sessions.

Namibia has been playing a significant role in HIV scientific advances on the African continent. It is appropriate that scientists, clinicians, program managers, students, and others from across Africa can get acquainted and appreciate the efforts that Namibia has made in combating HIV.

We hope that you will actively participate in virtual networking with Namibian, regional, and international conference participants through the INTEREST conference platform.

We wish you an enjoyable and educational conference!

Conference Chairs 2020



Objectives

Meeting Objectives

The INTEREST Conference aims to:

- Provide cutting-edge knowledge in the fields of treatment, pathogenesis, and prevention of human immunodeficiency virus (HIV) and related infections and chronic conditions;
- Exchange ideas on how to provide and support HIV testing services and clinical care provision to adults, adolescents, and children living with HIV in Africa to achieve 95-95-95 goals;
- Foster new research interactions among leading investigators and those who represent the potential future scientific leadership of health care and research on the African continent;
- Expand our focus on capacity building and implementation science.

Learning Objectives

After attending INTEREST, conference participants will:

- Have an improved knowledge of the most recent findings in HIV treatment, pathogenesis, and prevention research;
- Better understand the social determinants of health and HIV risk in order to contribute optimally to national, local, and individual HIV prevention strategies;
- Have learned about current guidelines and policies, as well as innovative programmes across the continent that are addressing HIV;
- Recognize challenges in the screening, monitoring, and diagnosis of patients living with HIV and be able to integrate the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV.



Practical Information

Abstracts

Accepted abstracts are published in **Reviews in Antiviral Therapy & Infectious Diseases, Volume 2020_10**.

You can download the abstract book here.

Certificate of Attendance

Certificates of attendance will be sent by e-mail in the week following the Conference after completion of the Feedback Forms.

Exhibition

Visiting the exhibition booths in the exhibition area will give you the opportunity to meet and network with key suppliers and industry leaders. This will help keep you up-to-date with the latest industry developments.

Feedback Forms

Your feedback is very valuable to us and enables us to further improve this conference. After each session a short questionnaire will pop-up and we would like ask you to take a minute to complete it. After the conference, a survey will be send to you via email, with other questions to improve this conference.

Group Picture

We ask you all to take a photo of yourself and send it to the INTEREST secretariat at rikke@vironet.com or lara@amededu.com. They will stitch it all together and send out the finished virtual group photo at the end of the conference.

Networking

Meet the other delegates by going to the networking area. Here you can join the general chat or chat with other delegates about certain topics like you would do at an actual conference.

Poster Gallery & Poster Viewing

During the virtual conference all accepted posters are displayed in the E-Posters Area. The E-Posters Area is always open for you.

Presentations and Webcasts

Webcasts of the presentations along with the PDF presentations will be available on

www.AcademicMedicalEducation.com

3 weeks after the meeting. You will be able to watch the presentations on the workshop portal until 3 weeks after the workshop: <https://interest2020.com/>.

Social Media

We encourage you to post news about INTEREST to your social media accounts and tweet about INTEREST as often as you like during the conference. You can either post your own tweet to your followers using the hashtag #INTEREST2010 or retweet a message through the official @INTERESTconf account.

Technical Problems

Should you encounter any technical problems, please contact us at rikke@vironet.com or lara@amededu.com.

Time Zones

Times are in Central Africa Time (CAT) / South African Standard Time (SAST). If you need to convert the times to your timezone, this website might be of interest to you:

<https://www.worldtimebuddy.com/>

Disclaimer: This Conference aims to offer participants the opportunity to share information. The Organisers of this conference, AIGHD and Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims that may result from the use of information or publications from this Conference.



Time Zones

MONDAY 30 NOVEMBER

	EST	WAT/CET	SAST/ EET	EAT
Session 1	06:30	12:30	13:30	14:30
Oral Abstract Presentations 1	07:35	13:35	14:35	15:35
Symposium - JnJ	08:35	14:35	15:35	16:35

TUESDAY 1 DECEMBER

	EST	WAT/CET	SAST/ EET	EAT
Session 2	06:30	12:30	13:30	14:30
Mini-Oral Abstract Presentations 1	07:35	13:35	14:35	15:35
Symposium - MSD	08:35	14:35	15:35	16:35

WEDNESDAY 2 DECEMBER

	EST	WAT/CET	SAST/ EET	EAT
Symposium - AbbVie	06:30	12:30	13:30	14:30
Oral Abstract Presentations 2	07:35	13:35	14:35	15:35
Symposium - ViiV	08:35	14:35	15:35	16:35

THURSDAY 3 DECEMBER

	EST	WAT/CET	SAST/ EET	EAT
Session 3	06:30	12:30	13:30	14:30
Mini-Oral Abstract Presentations 2	07:35	13:35	14:35	15:35
Session 4	08:35	14:35	15:35	16:35

FRIDAY 4 DECEMBER

	EST	WAT/CET	SAST/ EET	EAT
Session 5	06:30	12:30	13:30	14:30
Mini-Oral Abstract Presentations 3	07:35	13:35	14:35	15:35
IAS Session	08:35	14:35	15:35	16:35



Conference Organisers

Amsterdam Institute for Global Health and Development



The Amsterdam Institute for Global Health and Development (AIGHD) is an international research and education institute that works to develop sustainable solutions to major health problems. By taking a problem-oriented approach, AIGHD transcends the boundaries of traditional academic disciplines and integrates three fundamental activities into one institute: research, education, and policy. Founded by the late Professor Joep Lange in 2009, AIGHD brings together experts from multiple disciplines including biomedicine, economics, and social and behavioral sciences to address the most critical medical, social, economic, and political challenges in global health and development.

Virology Education



Virology Education (VE) is a leading provider of top quality, accredited programs for scientific interchange, knowledge sharing, and healthcare professional education. VE supports the healthcare community in discovering, researching, treating, and ultimately, curing viruses and infectious diseases. VE identifies needs, drives new initiatives, designs tailored programs, develops educational and scientific content, and handles logistical program management. Using a network of leading global experts, a database of 26,000 opt-in subscribers, and an in-house team of skilled professionals, Virology Education produces relevant, high-level content within the fields of HIV, hepatitis, co-infections, tuberculosis, emerging viruses, non-alcoholic steatohepatitis, liver disease, pharmacology, and oncology.



Committees



Local Organising Committee

Ismael Katjitae - National Technical Advisory Committee of the HIV/AIDS Response, Namibia

Anne-Marie Nitschke - Ministry of Health and Social Services, Namibia

Ndapewa Hamunime - Ministry of Health and Social Services, Namibia

Julieth Karirao- Ministry of Health and Social Services, Namibia

Norbert Forster - International Training & Education Center for Health, Namibia

Hilma Nangombe- Ministry of Health and Social Services, Namibia

Abigail Solomons - Positive Vibes Trust, Namibia

Veronica Theron - Office of the First Lady, Namibia

Leonard Bikenese - Ministry of Health and Social Services, Namibia

Fransina Frans- Ministry of Health and Social Services, Namibia

Tadesse Mekonen - Avacare Global, Namibia

David Uirab - Namibia Institute of Pathology, Namibia

Flavia Mugala Mukungu - Namibian HIV Clinicians Society, Namibia

Petrina Kapewangolo - University of Namibia, Namibia

Awafulo Omotayo- Namibia University of Science and Technology, Namibia

Honourable Dr. Kalumbi Shangula- Minister of Health and Social Services, Namibia



International Conference Committee



Anne-Marie Nitschke
Ministry of Health and Social
Services,
Namibia
Local Chair 2020



Ismael Katjitae
MD, MMed
National Technical Advisory
Committee of the HIV/AIDS
Response,
Namibia
Local Chair 2020



Catherine Hankins
MD, PhD, FRCPC
Amsterdam Institute
for Global Health and
Development,
Canada / The Netherlands
Scientific Chair



Elly Katabira
MD, FRCP
Makerere University College of
Health Sciences,
Uganda
Co-Chair



Charles Boucher
MD, PhD
Erasmus Medical Center, Rotterdam,
The Netherlands
Co-Founder



Linda-Gail Bekker
MBChB, FCP, PhD
Desmond Tutu HIV Foundation,
University of Cape Town,
South Africa



Elizabeth Bukusi
MBChB, MD, MPH, PhD
Kenya Medical Research
Institute,
Kenya



Guido Ferrari
MD
Duke University Medical Center,
United States



Pierre-Marie Girard
MD, PhD
Hôpital Saint-Antoine, Université
Pierre et Marie Curie,
France



James Hakim
MD
University of Zimbabwe College of
Health Sciences,
Zimbabwe



Andrew Kambugu
MBChB, MMed
Infectious Diseases Institute,
Makerere University College of
Health Sciences,
Uganda



Peter Kilmarx
MD, FACP, RADM
National Institutes of Health,
Fogarty International Center,
United States



International Conference Committee



**Nagalingeswaran
Kumarasamy
MD**
YRG Centre for AIDS
Research and Education,
India



**Kwasi Torpey
MD**
University of Ghana,
Ghana



**Chewe Luo
MD, PhD**
UNICEF, United States /
University Teaching Hospital,
Zambia



**Timothy Mastro
MD, FACP, DTM&H**
FHI 360, University of North Carolina
at Chapel Hill,
United States



**Sam Phiri
DCM, PhD, MSc**
Partners in Hope
Malawi



**Anna Laura Ross
PhD**
UNITAID,
Switzerland



**Coumba Touré Kane
PharmD, PhD**
Laboratoire de Bacteriologie-
Virologie CHU Le Dantec, Dakar
University,
Senegal



**François Venter
MBCCH, MMed, FCP (SA), DTM&H**
University of the Witwatersrand,
South Africa



**Stephen Watiti
MD**
Mildmay Hospital,
Uganda



Emeritus Group

Serge Eholié, MD, PhD - CHU de Treichville, University of Abidjan, Ivory Coast

Grace John-Stewart, MD, PhD, - University of Washington, United States

Saidi Kapiga, MD, MPH, ScD - Mwanza Intervention Trials Unit (NIMR)/LSHTM, Tanzania / United Kingdom

Sinata Koulla, MD - Ministry of Health, Cameroon

Richard Koup, MD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID),
United States

Sabin Nsanzimana, MD, PhD - Rwanda Biomedical Center, Rwanda

Anton Pozniak, MD - Chelsea and Westminster Hospital NHS Foundation Trust and Imperial College of
London, United Kingdom

Helen Rees, MD - WITS Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand,
South Africa

Robert Schooley, MD - University of California, United States

Mauro Schechter, MD, PhD - Federal University Rio de Janeiro, Brazil

Stefano Vella, MD - Istituto Superiore di Sanità, Italy

Debrework Zewdie, PhD - CUNY School of Public Health and Public Policy, United States

Our Team



Karin Siebelt
Project Manager
karin@vironet.com



Marloes Nijboer
Project Manager
m.nijboer@aighd.org



Rikke Rode
Project Coordinator
rikke@vironet.com



Jacqueline Weiner
Communications Manager
j.weiner@aighd.org



Lara Da Sliva Miguel
Project Coordinator
lara@amededu.com



Programme



Programme

MONDAY, 30 NOVEMBER

Times are in South African Standard Time (SAST) / Central African Time (CAT)

- 13:30 **Welcome from the Conference Co-chairs**
Anne-Marie Nitschke - Local Chair
Ministry of Health and Social Services, Namibia
Ismael Katjitae - Local Chair
National Technical Advisory Committee of the HIV/AIDS response, Namibia
Elly Katabira, MD, FRCP - Co-Chair
Makerere University College of Health Sciences, Uganda
Catherine Hankins MD, PhD, FRCPC, CM - Scientific Chair
Amsterdam Institute for Global Health and Development, Canada / The Netherlands
Honorable Dr. Kalumbi Shangula
Minister of Health & Social Services, Namibia

Session 1 - Opening

Chairs: Elly Katabira (Uganda) and Catherine Hankins (Canada / The Netherlands)

- 13:35 **Introduction**
Elly Katabira, MD, FRCP
Makerere University College of Health Sciences, Uganda
Catherine Hankins, MD, PhD, FRCPC, CM
Amsterdam Institute for Global Health and Development, Canada / The Netherlands
- 13:36 **Impact of COVID-19 on HIV, Tuberculosis, and Malaria Epidemiology and Treatment Services Across Africa**
John Nkengasong, MSc, PhD
Director of the Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
- 13:51 **HIV and Climate Change: the Research Opportunities**
Matthew Chersich, MBBCh, MSc, PhD
University of the Witwatersrand, South Africa
- 14:06 **Q & A**

14:20 Tea Break

Oral Abstract Presentations 1

Chairs: Elizabeth Bukusi (Kenya) and Peter Kilmarx (United States)

- 14:35 **Introduction**
- 14:36 The Effect of Hazardous Drinking on Key HIV Outcomes among HIV-Positive Men: Results from Six Population-Based HIV Impact Assessments Completed in Sub-Saharan Africa (2015-2018) Gregory Chang, United States #3
- 14:44 The Frequency and Yield of Cryptococcal Antigen Screening among Newly Diagnosed and Anti-Retroviral Therapy Experienced HIV Patients in Rural Uganda Joseph Baluku, Uganda #4
- 14:52 Cost-Utility Analysis of Dolutegravir-Versus Efavirenz 400mg-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon: 96-week Results from the NAMSAL ANRS 12313 Trial Marwan al Qays Bousmah, France #2
- 15:00 What Shapes Resilience Among People Living with HIV? A Multi-Country Analysis of Data from the PLHIV Stigma Index 2.0 Stella Kentusi, Uganda #1
- 15:08 **Q & A**



Programme

15:20 Tea Break

Symposium 1 - Johnson & Johnson - Innovations in the prevention and treatment of HIV

Chair: Yunus Moosa (South Africa)

15:35 **Welcome, Introduction and Objectives**

Yunus Moosa

South Africa

15:37 **Understanding Innovations in HIV Prevention**

Francois Venter

South Africa

15:49 **Understanding Innovations in HIV Treatment**

Kogieleum Naidoo

South Africa

16:01 **Group discussion: Practical considerations what can be done to ensure that vulnerable populations and young people benefit from such innovations?**

16:16 **Close**

16:20 Closure Day 1

Catherine Hankins MD, PhD, FRCPC, CM

Amsterdam Institute for Global Health and Development, Canada / The Netherlands



TUESDAY, 1 DECEMBER

Times are in South African Standard Time (SAST) / Central African Time (CAT)

- 13:30 **Welcome to Day 2**
Ismael Katjitae
 National Technical Advisory Committee of the HIV/AIDS response, Namibia

Session 2 -HIV Prevention

Chair: Elizabeth Bukusi (Kenya) and Timothy Mastro (United States)

- 13:35 **Introduction**
Elizabeth Bukusi, MBChB, MMed, MPH, PhD
 Kenya Medical Research Institute, Kenya
Timothy Mastro, MD, FACP, DTM&H
 FHI 360, United States
- 13:36 **Progress on New Antiretroviral Formulations and Monoclonal Antibodies for HIV Prevention**
Nyaradzo Mavis Mgodzi, MBChB, MMed
 University of Zimbabwe Clinical Trials Research Centre, Zimbabwe
- 13:51 **The ECHO Trial: What's Next on Contraception and HIV: Policy, Practice, and Research?**
Margaret Phiri Kasaro, MBChB, MSc
 University of North Carolina Global Project Zambia (UNC GPZ), Zambia
- 14:06 **Q & A**

- 14:20 Tea Break

Mini-Oral Abstract Presentations 1

Chairs: Sam Phiri (Malawi) and Anne-Laura Ross (Switzerland)

- 14:35 **Introduction**
- 14:36 Striving Towards HIV Epidemic Control through Reaching a Population in Correctional Facilities in Namibia Hilaria Ashivudhi, Namibia #26
- 14:39 Index-Linked HIV Testing for Children and Adolescents in Health Facility and Community-Based Settings in Zimbabwe: Findings from the B-GAP Study Chido Dziva Chikwari, Zimbabwe #24
- 14:42 Perceptions, Preferences and Access to Community-Based HIV Testing Services among Men who have Sex with Men (MSM) in Côte d'Ivoire Maxime Inghels, United Kingdom #23
- 14:45 "It is Better if you are Going to Test Yourself...": Attitudes, Test Preferences and Challenges of HIV Self-Testing among Female Sex Workers in eThekweni, South Africa: the Siyaphanta study Kedibone Sithole, South Africa #33
- 14:48 Traditional Healers Can Increase Uptake of HIV Testing among Adults of Unknown Serostatus: Results from a Cluster Randomized Pilot Study in Southwestern Uganda Radhika Sundararajan, United States #37



Programme

14:51	A Gap Analysis and Total Quality Leadership and Accountability Intervention Triples HIV Testing Yield among Key Population in Zambia	Florence Tembo Mulenga, Zambia	#18
14:54	Gaining Traction: Promising Shifts in Gender Norms and Intimate Partner Violence During an HIV prevention Trial in South Africa	Ann Gottert, United States	#13
14:57	Case Series of Urethrocutaneous Fistulas After Voluntary Medical Male Circumcision for HIV Prevention—15 African Countries, 2015–2019	Todd Lucas, United States	#34
15:00	Is the Use of Creatinine Clearance Test at Baseline for PrEP Enrolment Necessary in Resource-Constrained Settings?	David Chilongozi, Malawi	#15
15:03	Q & A		

15:20 Tea Break

Symposium 2 - MSD - HIV in Africa: Challenges and Opportunities

Chair: Linda-Gail Bekker (South Africa)

15:35	Opening and Welcome Linda-Gail Bekker Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of Health Sciences University of Cape Town, South Africa		
15:36	PrEP: Where We Need to Go? Linda-Gail Bekker Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of Health Sciences University of Cape Town, South Africa		
15:51	Treatment: Have we Reached the Final Mile Tendani Gaolathe Botswana Harvard AIDS Institute Partnership (MOH) University of Botswana School of Medicine Gaborone, Botswana		
16:06	Panel Discussion and Q & A Linda-Gail Bekker Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of Health Sciences University of Cape Town, South Africa		

16:20 Closure Day 2

Ismael Katjitae

National Technical Advisory Committee of the HIV/AIDS response, Namibia



WEDNESDAY, 2 DECEMBER

Times are in South African Standard Time (SAST) / Central African Time (CAT)

13:30 **Welcome to Day 3**
Elly Katabira, MD, FRCP
 Makerere University College of Health Sciences, Uganda

Symposium 3 - AbbVie - Evolving HIV Clinical Pathway: Approaches to Combine Rapidly Changing Guidelines and Sustainability of Anti-Retroviral Treatment in Resource Limited Settings.
 Chair: Andrew Kambugu (Uganda)

13:35 **Opening and Welcome**
Andrew Kambugu
 Uganda

13:40 **Speaker 1**
Jeremy Nel
 South Africa

13:55 **Speaker 2**
Albert Mwango
 Zambia

14:10 **Open Discussion, Q & A**
All

14:19 **Final Remarks & Closing**
Andrew Kambugu
 Makerere University College of Health Sciences, Uganda

14:20 Tea Break

Oral Abstract Presentations 2
 Chairs: Flavia Mugala (Namibia) and James Hakim (Zimbabwe)

14:35 **Introduction**

14:36 Monitoring and Management of Treatment Failure Among People on Antiretroviral Therapy in Mozambique: Lessons Learned to Improve Treatment Effectiveness Laura Marcela Torres, Mozambique #6

14:44 Rapid Antiretroviral Therapy Initiation and the Risk of Mortality and Loss to Follow-Up in Children with HIV Peter James Elyanu, Uganda #7

14:52 High Levels of HIV Drug Resistance in Adult Patients with Unsuppressed Viral Load, Measured Through Routine Viral Load Programme Monitoring in South Africa, 2019 Gillian Hunt, South Africa #5

15:00 Effect of Same-Day ART Initiation on Early Retention in Rakai, Uganda Jesca Basiima, Uganda #8

15:03 **Q & A**



Programme

15:20 Tea Break

Symposium 4 - ViiV - The ART of Paediatric HIV: An African Perspective

Chair: Michelle Kisare (Kenya)

15:35 **Opening and Welcome**

Michelle Kisare

Kenya

15:40 **Evolution of Paediatric HIV Management in Africa**

Mark Cotton

South Africa

16:00 **The Role of Dolutegravir in Paediatric HIV Management**

Serufusa Sekidde

United Kingdom

16:10 **Question and Answer session**

All

16:20 Closure Day 3

Elly Katabira, MD, FRCP

Makerere University College of Health Sciences, Uganda



THURSDAY, 3 DECEMBER

Times are in South African Standard Time (SAST) / Central African Time (CAT)

- 13:30 **Welcome to Day 4**
Anne-Marie Nitschke - Local Chair
 Ministry of Health and Social Services, Namibia

Session 3 - Access to Medicines and TB

Chairs: Ndapewa Hamunime (Namibia) and Frank Cobelens (The Netherlands)

- 13:35 **Introduction**
Ndapewa Hamunime, MD, MBA
 Ministry of Health and Social Services, Namibia
Frank Cobelens
 University of Amsterdam / Amsterdam Institute for Global Health and Development, The Netherlands
- 13:36 **What you Need to Know about Public-Health Licensing and Access to Medicines in Africa**
Sébastien Morin
 Medicines Patent Pool, Switzerland
- 13:51 **TB State-of-the-Art: Implications for Africa**
Dereck Tait, MBChB
 IAVI, South Africa
- 14:06 **Q & A**

- 14:20 Tea Break

Mini-Oral Abstract Presentations 2

Chairs: Catherine Hankins (Canada / The Netherlands) and Anton Pozniak (United Kingdom)

- 14:35 **Introduction**
- 14:36 Current Approaches for Identifying and Managing HIV Treatment Failure Among Children, Adolescents, and Young People In Sub-Saharan Africa: Multi-Country Experience from the New Horizons Collaborative
 Natella Rakhmanina, #36
 United States
- 14:39 Syndemic of Hepatitis B and C and Their Coinfection With HIV in Rwanda: Role of Unsafe Medical Practices and Sexual Behaviors
 Jean Damascene #17
 Makuza, Rwanda
- 14:42 Patient-Reported Outcomes After Direct-Acting Antiviral Treatment for Chronic Hepatitis C in West And Central Africa: The ANRS 12311 TAC Trial
 Fabienne Marcellin, #14
 France
- 14:45 Prevalence, Risk and Protective Factors for Common Mental Disorders Among Young People Living With HIV Compared to Their Uninfected Peers From the Kenyan Coast: A Cross Sectional Study
 Moses Kachama #29
 Nyongesa, Kenya
- 14:48 Trends in Transmitted Drug Resistance in A Cohort Of ART-Naive HIV-1 Infected Individuals in Ethiopia
 Mulugeta Kiros, #16
 Ethiopia



Programme

- | | | | |
|-------|--|---------------------------------|-----|
| 14:51 | Using A Quality Improvement Collaborative Approach to Improve Tuberculosis Prevention Therapy Coverage in The Kavango Region, Namibia | Apollo Basenero, Namibia | #32 |
| 14:54 | For Each Hour a Patient Living with HIV Spends in the Health Facility, the Probability of Being Retained in Care Decreases: Results from a Patients' Satisfaction Survey in Mozambique | Caroline De Schacht, Mozambique | #12 |
| 14:57 | Does Navigated Linkage to Care Work? A Cross-Sectional Study of Active Linkage to Care Within an Integrated Non-Communicable Disease | Kathryn Hopkins, South Africa | #11 |
| 15:00 | Q & A | | |

15:20 Tea Break

Session 4 - STI and Implementation Science

Chairs: François Venter (South Africa) and Kwasi Torpey (Ghana)

- | | | | |
|-------|--|--|--|
| 15:35 | Introduction
François Venter, MBCCH, MMed, FCP (SA), DTM&H
University of the Witwatersrand, South Africa
Kwasi Torpey, MD, PhD, MPH, FGCP
University of Ghana College of Health Sciences, Ghana | | |
| 15:36 | What's New in Sexually Transmitted Infections and HIV in 2020
Rashida Ferrand, FRCP, PhD
London School of Hygiene and Tropical Medicine / Biomedical Research and Training Institute, Zimbabwe | | |
| 15:51 | Implementation Science - an African Perspective
Peter Cherutich, MBChB, PhD, MPH
Ministry of Health, Kenya | | |
| 16:06 | Q & A | | |

16:20 Closure Day 4

Anne-Marie Nitschke

Ministry of Health and Social Services, Namibia



FRIDAY, 4 DECEMBER 2020

Times are in South African Standard Time (SAST) / Central African Time (CAT)

- 13:30 **Welcome to Day 5**
Catherine Hankins MD, PhD, FRCPC, CM
 Amsterdam Institute for Global Health and Development, Canada / The Netherlands

Session 5 - Distance Learning and Dolutegravir Controversy

Chairs: Anna Laura Ross (Switzerland) and Sam Phiri (Malawi)

- 13:35 **Introduction**
Anna Laura Ross, PhD
 UNITAID, Switzerland
Sam Phiri, DCM, PhD, MSc
 Partners in Hope, Malawi
- 13:36 **Engaging in Collaborative Hands-On Learning: Building the Response in Africa**
Leonard Bikinesi, MD
 Ministry of Health and Social Services, Namibia
- 13:51 **Dolutegravir and Weight Gain - Where are We?**
François Venter, MBCCH, MMed, FCP (SA), DTM&H
 University of the Witwatersrand, South Africa

- 14:06 **Q & A**

- 14:20 Tea Break

Mini-Oral Abstract Presentations 3

Chairs: Elly Katabira (Uganda) and Peter Kilmarx (United States)

- 14:35 **Introduction**
- 14:36 Adverse Event Notification and Tracking Among HIV Positive Patients on ART: Lessons from A Tele-Health Centre In Kampala Joram Okeng, #10
 Uganda
- 14:39 Creating a Safe Space for Key Populations Within Health Facilities: Experience from Montserrado County, Liberia Gift Kamanga, #9
 Liberia
- 14:42 Stakeholder Participation in The Establishment of One-Stop Shops and Key Population-Friendly Facilities: Descriptive Lessons from the FHI 360 GF Project Chidubem Oraelosi, #27
 Nigeria
- 14:45 Incident HIV Infection Among Pregnant Women in The South African 2017 Antenatal Survey: Assay-Based Incidence Measurement Selamawit Woldesenbet, #20
 South Africa
- 14:48 Cost of Antiretroviral Therapy Services Among Patients Who Achieved Viral Suppression: A Case Study Of 9 ART Clinics in Namibia Ndapewa Hamunime, #31
 Namibia
- 14:51 Alarming Burden of Dual-Class HIV-1 Drug Resistance Among Adolescents Calls for Innovative Antiretroviral Strategies: Baseline Findings from the Ready-Study (EDCTP TMA 1027) Armanda Nangmo, #25
 Cameroon



Programme

14:54	Positive Effects of Intensified Preventive Calls/Home Visits on Early Retention Among Adults Newly Initiated on Antiretroviral Therapy in Zambézia Province, Mozambique	José Tique, Mozambique	#38
14:57	Short-Cycle Therapy in HIV-Infected Adults: 4 days on / 3 days off with Combinations Containing Rilpivirine	Dora Luise, Italy	#22
15:00	Transcriptional Analysis of Lymph Node Derived Follicular CD4 T Cells Reveal Novel Phenotypic Markers and Functions of T Follicular Regulatory (TFR) Cells	Bongiwe Mahlobo, South Africa	#21
15:03	Q & A		

15:20 Tea Break

Symposium 5 - IAS - "Getting to the Heart of Stigma: What does it take to have an impact at scale?"
Chair: Lucy Stackpool-Moore (Switzerland)

15:35	Adeeba Kamarulzaman Malaysia
	Edwin Cameron South Africa
	Kate Thomson Switzerland
	Thomas Muchimba Buttenschon Denmark
	Laura Ferguson United States
	Rt Hon Given Katuta Zambia

Closing Session

16:20	Joep Lange Award
16:25	Anne-Marie Nitschke Ministry of Health and Social Services, Namibia
	Ismael Katjitae National Technical Advisory Committee of the HIV/AIDS response, Namibia
	Elly Katabira, MD, FRCP - Co-Chair Makerere University College of Health Sciences, Uganda
	Catherine Hankins MD, PhD, FRCPC, CM - Scientific Chair Amsterdam Institute for Global Health and Development, Canada / The Netherlands



Acknowledgements

ENDORSED BY



Acknowledgements

CORPORATE SUPPORT

GOLD LEVEL

abbvie *Johnson & Johnson*



Working together in HIV

BRONZE LEVEL

 **VIATRIS** | Mylan + Upjohn

PRINCIPLE SUPPORTER LEVEL



National Institute of Allergy and Infectious
Diseases, National Institutes of Health

CONTRIBUTOR LEVEL





Working together in HIV

**FOR THE
38 MILLION
UNTIL IT'S ZERO**

**WE ARE HERE
UNTIL THE DAY
WE BEAT HIV**

SE-NA-HVX-ADVR-200001
Date of preparation: November 2020



**POSITIVELY
COMMITTED**

...together, for 35 years and counting





We blend , Science and Ingenuity to profoundly change the trajectory of health for humanity.

Johnson & Johnson presents a virtual symposium on the latest innovative developments in the prevention and treatment of HIV.

Monday, 30 November 2020

15:35 – 16:20 SAST

Annual INTEREST Conference

Our Mission

End HIV transmission by accelerating adoption of transformational innovation in resource limited settings

Our Vision

#MakeHIVHistory

Learn more at www.jnj.com/gph and follow us [@JNJGlobalHealth](https://twitter.com/JNJGlobalHealth)

At AbbVie, we strive to make a remarkable impact on the lives of patients.

We are a global, research-based biopharmaceutical company committed to discovering, developing and delivering innovative new medicines with distinct and compelling benefits for people. Today, our medicines help 52 million* people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines.

We are a passionate, diverse and inclusive organization with a culture that supports the best ideas, wherever they originate. We bring people together because we know that collaboration is the key to breaking barriers and exploring new frontiers in science. We take smart risks that lead to transformative breakthroughs and can change lives for people all over the globe.

Our commitment to making a remarkable impact doesn't end at developing medicines; it begins there. We provide broader support to our patients and help address the health needs of underserved communities. We strive to protect our environment and to make a positive impact in the areas where we live and work.

*52 million is the total number of patients served by AbbVie products in 2019.

AbbVie (Pty) Ltd, Reg. 2012/068113/07. Abbott Place, 219 Golf Club Terrace, Constantia Kloof, 1709, South Africa. Tel: 011 831 3200, Fax: 011 831 3292. Date of Publication of this Material: November 2020. ZA-ABBV-200058



INTEREST